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Renal Cell Carcinoma in Kidney Transplant Recipients and Dialysis 
Patients
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Purpose: In a group of surgery patients diagnosed with renal cell cancer, those who un-
derwent dialysis were compared with those who received a kidney transplant. 
Materials and Methods: The 43 subjects included in this study were patients who had 
been undergoing dialysis because of end-stage renal disease or had undergone kidney 
transplantation. The patients were diagnosed with renal cell carcinoma (RCC) during 
follow-up and underwent radical nephrectomy from May 1996 to December 2010. Their 
medical records were retrospectively analyzed as part of the study.
Results: In the transplantation group, the renal replacement therapy period averaged 
54 months, and the period from transplantation to RCC averaged 119 months (range, 
0 to 264 months). In the dialysis group, RCC was observed after an average of 124 
months (range, 2 to 228 months) of dialysis, and nephrectomy was then conducted. 
Acquired cystic kidney disease (ACKD) was found more frequently in the dialysis group, 
and it had a statistically relevant effect on the occurrence of RCC by comparison with 
the transplantation group (p＜0.01). 
Conclusions: Although the incidence rate of ACKD was significantly higher in the dialy-
sis group among patients undergoing surgery for RCC, cancer was found even without 
ACKD development in some transplant recipients. Considering that the transplant re-
cipients also underwent dialysis, an informative prospective study will be necessary 
to determine whether other immunosuppressive agents besides ACKD may function 
as a cancer risk factor.
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INTRODUCTION
Renal cell carcinoma (RCC) accounts for approximately 2 
to 3% of cancer in adults of the general population. 
Compared with other types of cancer, RCC is difficult to di-
agnose and shows different clinical patterns [1]. In partic-
ular, RCC is associated with such a low survival rate in kid-
ney transplantation patients that studies on the correla-
tion between the transplantation and the cancer have re-
cently been conducted [2]. 
After diagnosis with end-stage renal disease (ESRD), 
transplantation patients take immunosuppressive agents 
for preservation of the transplanted kidney, and the use of 
such agents since the 1970s has been reported to raise the 
occurrence of malignancy [2]. Immunosuppressant ther-
apy was used in the past to prevent rejection, but this type 
of therapy has actually decreased the survival rate by in-
creasing cancer occurrence [3]. The incidence rate of cancer 
in patients using immunosuppressive agents is approx-
imately 2 to 5 times higher than in healthy controls. 
According to a previous study, the incidence rate of cancer 
is 10 times higher in renal transplant recipients than in di-
alysis patients [4].
Acquired cystic kidney disease (ACKD) is known to be 
frequently observed in dialysis patients with chronic renal 
failure and patients using immunosuppressive agents af-Korean J Urol 2012;53:229-233
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ter transplantation [5]. In particular, ACKD needs careful 
follow-up as a pre-malignant lesion. ACKD is found mainly 
in patients on dialysis, and its existence influences the oc-
currence of cancer. ACKD was reported to be observed in 
20% of patients on dialysis for 1 to 3 years and in ＞90% of 
those on dialysis for 5 to 10 years [5]. ACKD increases the 
prevalence of RCC by around 20%. For transplant recipi-
ents among ESRD patients undergoing dialysis, the in-
cidence rate of RCC is known to be 40 to 100 times higher 
than in healthy controls [6].
Previous studies investigated only the occurrence of 
ACKD and RCC in dialysis patients and the occurrence of 
RCC in the native kidney after kidney transplantation. 
There have been no reports comparing dialysis patients 
and transplant recipients among RCC patients. 
In the present study, we examined ACKD development 
and the correlation between dialysis duration and the oc-
currence of RCC. Two groups of patients were defined from 
among those who had been diagnosed and surgically treat-
ed for RCC: those who had undergone kidney trans-
plantation (±dialysis) and those who had undergone dialy-
sis only. The purpose of this investigation was to determine 
whether there was a pathologic difference between the two 
groups.
MATERIALS AND METHODS
The study included 43 patients diagnosed with RCC during 
follow-up among patients undergoing dialysis owing to 
ESRD and renal transplant recipients. The patients’ medi-
cal records were analyzed for age, age at radical neph-
rectomy, age at starting dialysis, duration of dialysis 
(months), duration of use of immunosuppressive drugs 
(months), gender, medical history, type of dialysis, dialysis 
after transplantation, routine examination, presentation 
of ACKD, and symptoms for RCC evaluation, retrospec-
tively. We took an examination of all patients by computed 
tomography (CT). ACKD was found by CT by a radiologist. 
The patients were diagnosed with RCC and underwent 
radical nephrectomy or renal biopsy from May 1996 to 
December 2010.
For the classification of RCC cell type, mixed histologic 
type was considered as a dominant pattern. Tumor stage 
was determined by the tumor size, metastasis to node, and 
metastasis classification and cellular grade was classified 
as G1 to G4.
All data were analyzed by univariate analysis. The 
chi-square test was used with nominal variables; Student’s 
t-test was used with continuous variables. The p-values of 
＜0.05 were considered to be significant. Statistical analy-
ses were conducted by using IBM SPSS ver. 18.0 (IBM Co., 
New York, NY, USA).
RESULTS
This study compared dialysis patients and transplant re-
cipients who had been diagnosed with RCC and had been 
surgically treated. As summarized in Table 1, the mean age 
of the transplantation and dialysis groups was 57±11 and 
52±11 years, respectively. Comparison between the two 
groups did not show any significant differences in gender 
distribution (p=0.82), blood pressure (p=0.89), or the ex-
istence of diabetes (p=0.14) (Table 1). 
In 42 cases among the total patients, RCC was diagnosed 
through radical nephrectomy, and in the other 1 case it was 
pathologically confirmed through renal biopsy. Of the 43 
patients, 21 underwent kidney transplantation after dialy-
sis, and the other 22 were on dialysis. Of the 21 patients 
who underwent kidney transplantation, 13 patients had 
histories of prior hemodialysis (HD) treatment. Whereas 
six patients underwent only peritoneal dialysis (PD), two 
patients had undergone kidney transplantation without 
dialysis after being diagnosed with ESRD. Ten patients de-
veloped post-transplantation acute or chronic rejection, 
and six of these were on dialysis because of rejection of the 
transplanted kidney. The duration of dialysis following re-
jection was less than 1 month, and the transplanted kidney 
could be saved after dialysis or by using immunosu-
ppressive agents. One patient underwent a second trans-
plantation owing to chronic rejection. In addition, one pa-
tient developed membranoproliferative glomeruloneph-
ritis, which was dealt with by removal of the transplanted 
kidney and treatment with PD. The remaining patients 
were treated by immunosuppressive agents. Among the 22 
dialysis patients, seven men received HD, whereas 12 pa-
tients received PD. Three patients switched during treat-
ment from PD to HD (Table 1).
Of the total of 7,009 dialysis patients in our hospital, 0.3% 
(22 patients) were surgically treated for RCC, and 82% of 
those (18 patients) had ACKD. Among the total of 2,757 re-
nal transplant recipients in our hospital, 0.8% (21 patients) 
were diagnosed with RCC, and 5% (1 patient) of those had 
ACKD (Table 1).
In the transplantation group, the subjects underwent 
transplantation after an average period of 54 months 
(range, 0 to 168 months) of renal replacement therapy, and 
the average period from transplantation to nephrectomy 
due to RCC was 119 months (range, 0 to 264 months). In 
the dialysis group, RCC was found after an average of 124 
months (range, 2 to 228 months) of dialysis and was treated 
by nephrectomy. The transplantation subjects underwent 
mainly HD, and dialysis subjects in most cases received PD 
treatment. However, the difference in dialysis modality 
had no statistical significance with respect to the occur-
rence of RCC (p=0.14) (Table 1).
In the transplantation group, we took a routine examina-
tion by ultrasonogram or CT (22 patients). The dialysis 
group did not undergo a routine examination by ultrasono-
gram or CT except for one patient in whom another cancer 
was diagnosed (Table 1). 
For symptoms leading to RCC evaluation, RCC was sus-
pected coincidentally during follow-up by CT or ultra-
sonography in 8 patients (38%) of the transplantation 
group and in 9 (41%) of the dialysis group. When RCC char-Korean J Urol 2012;53:229-233
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TABLE 1. Patient characteristics before renal cell cancer (RCC) diagnosis
Characteristic Transplantation Dialysis Total p-value
Age (yr)
Age at radical nephrectomy (yr)
Age at starting dialysis (yr)
Duration of dialysis (mo)
Duration of use of immunosuppressive drug (mo)
Sex 
Male
Female
HTN
Yes
No
DM
Yes
No
Rejection
Yes
No
Type of dialysis
HD
PD
HD＋PD
Transplantation only
Dialysis after transplantation
Yes
No
Routine examination
Yes
No
ACKD
Yes
No
Symptoms for RCC evaluation
Fever
Flank pain
Coincidence
Hematuria
Other
57±11 (42-74)
55±10 (40-71)
36.5±9.4 (20-59)
54±59 (0-168)
119±74 (0-264)
15 (71)
6 (29)
11 (52)
10 (48)
2 (10)
19 (90)
10 (48)
11 (52)
13 (62)
6 (29)
-
2 (9)
6 (29)
15 (71)
21 (100)
0 (0)
1 (5)
20 (95)
3 (14)
2 (10)
8 (38)
2 (10)
6 (28)
52±11 (28-69)
47±11 (25-64)
36.6±10.6 (14-56)
124±60 (2-228)
15 (65)
7 (35)
12 (55)
10 (45)
0 (0)
22 (100)
-
-
7 (32)
12 (55)
3 (13)
-
-
-
1 (5)
21 (95)
18 (82)
4 (18)
3 (14)
3 (14)
9 (42)
3 (14)
4 (16)
30 (70)
13 (30)
23 (53)
20 (47)
2 (5)
41 (95)
20 (47)
18 (42)
3 (7)
2 (4)
22 (51)
21 (49)
19 (44)
24 (56)
6 (14)
5 (12)
17 (40)
5 (12)
10 (22)
0.76
0.78
0.60
0.49
0.82
0.89
0.14
-
0.14
-
＜0.01
＜0.01
0.93
Values are presented as mean±SD (range) or number (%).
HTN, hypertension; DM, diabetes mellitus; HD, hemodialysis; PD, peritoneal dialysis; ACKD, acquired cystic kidney disease.
acteristics were investigated after the surgery, there were 
no statistically significant differences in the cancers as to 
side of occurrence (p=0.2), cell type (p=0.85), Fuhrman 
grade (p=0.91), T stage (p=0.27), N stage (p=0.36), or M 
stage (p=0.36) between the two groups (Table 2).
ACKD was found more often in the dialysis group, and 
it affected the occurrence of RCC in the comparison with 
the transplantation group (p＜0.01) (Table 1, 3).
DISCUSSION
Since Dunnill et al. [7] first referred in 1977 to the correla-
tion between RCC and ACKD following ESRD, some stud-
ies have confirmed a relationship between ESRD and the 
occurrence of RCC. In 1992, Chandhoke et al. [8] found no 
correlation between the two. However, in 2006 Moudouni 
et al. [4] observed that the incidence of RCC in the native 
kidney was high in transplant recipients, and Kojima et al. 
[9] reported that the incidence rate was high in dialysis 
patients. In the latter study, it was shown that 44 (1.68%) 
of 2,624 ESRD patients followed up during dialysis devel-
oped RCC an average of 11.2 years after dialysis, and 36 
of these cases (81.8%) were associated with ACKD. A pos-
itive correlation with the incidence rate of RCC was also 
found among transplant recipients [9]. In 2007, Ianhez et 
al. [10] reported that 10 of 1,375 patients developed RCC 
of the native kidney an average of 8.4 years after renal re-
placement therapy, and all the RCC cases were associated 
with ACKD. Pope et al. [11] showed in a study of 7 kidney 
transplantation patients and 13 dialysis patients in 1994 Korean J Urol 2012;53:229-233
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TABLE 2. Clinical and pathologic data for patient with renal cell 
cancer (RCC) in renal replacement therapy
Transplan-
tation
Dialysis Total p-value
Location
Right
Left
Bilateral
Cell type
Clear cell
Papillary
Other
Fuhrman grade
1
2
3
4
T stage
a
1
2
3
4
N stage
a
0
1
M stage
a
0
1
10 (48)
11 (52)
0 (0)
12 (57)
  6 (29)
  3 (14)
  7 (33)
10 (48)
  3 (14)
1 (5)
16 (73)
  3 (14)
1 (5)
0 (0)
19 (90)
1 (5)
19 (90)
1 (5)
  8 (36)
11 (50)
  3 (14)
14 (64)
  6 (27)
2 (9)
  7 (32)
  9 (41)
  5 (23)
1 (4)
21 (95)
1 (5)
0 (0)
0 (0)
  22 (100)
0 (0)
  22 (100)
0 (0)
18 (42)
22 (51)
3 (7)
26 (60)
12 (28)
  5 (12)
14 (33)
19 (44)
  8 (19)
2 (4)
37 (86)
4 (9)
1 (2)
0 (0)
41 (95)
1 (2)
41 (95)
1 (2)
0.20
0.85
0.91
0.27
0.36
0.36
Values are presented as number (%).
a: One patient underwent renal biopsy only (transplanted group).
TABLE 3. Clinical and pathological data in patients by acquired 
cystic kidney disease (ACKD)
ACKD (+) ACKD (-) p-value
Transplantation group
Dialysis group
Total
Hx
HTN
DM
T stage
a
1
2
3
4
N stage
a
0
1
M stage
a
0
1
FG grade　
1
2
3
4
Transplantation group (21)
Male
Female
Age
Duration of dialysis
Dialysis group (22)
Male
Female
Age
Duration of dialysis
  1
18
19
10/19
  0/19
19
  0
  0
  0
19
  0
19
  0
  8
  7
  5
  0
  1
  0
56.5±14.8
39.0±46.7
13
  5
53.1±9.5
133.6±58.7
20
  4
24
10/24
2/24
18
  4
  1
  0
22
  1
22
  1
  6
12
  3
  2
14
  6
56.58±10.7
  55.5±62.7
  2
  2
  46.7±16.4
  81.5±54.7
＜0.01
0.67
0.18
0.76
0.34
0.27
0.27
0.49
0.71
0.18
0.74
0.41
0.75
Hx, patients past medical history; HTN, hypertension; DM, dia-
betes mellitus; FG, Fuhrman grade.
a: One patient underwent renal biopsy, only (transplanted group). 
that the pathologic appearance was not significantly differ-
ent between the two groups but the stage and mortality 
were higher in the kidney transplantation group. They sug-
gested the use of immunosuppressive agents for the trans-
plant recipients as a reason for the finding. 
In this study, analysis of all the pathological findings, in-
cluding cell type (p=0.85), Fuhrman grade (p=0.91), T stage 
(p=0.27), N stage (p=0.36), and M stage (p=0.36), showed 
no statistically significant differences between the trans-
plantation and dialysis groups (Table 2). One reason for 
this lack of significant difference could be the time at de-
tection before the surgery. Symptoms of RCC are generally 
nonspecific. Because the risk of cancer is high in transplant 
recipients, as shown in previous studies, our hospital rou-
tinely conducts ultrasonography. Thus, we could detect ab-
normalities by ultrasonography earlier, and it is more usu-
al to identify RCC in screening by CT after finding an abnor-
mality by ultrasonography. In addition, most of the renal 
replacement patients with symptoms underwent CT for 
early detection of RCC. 
The correlation between dialysis and ACKD should be 
mentioned. In 1990, Matson and Cohen [5] investigated 
ACKD development and its correlation with RCC among 
ESRD patients. They demonstrated that ACKD was close-
ly correlated with the duration of renal replacement ther-
apy but not with the type of dialysis that was performed. 
Many studies on transplantation and ACKD have also 
reported that ACKD is observed more frequently, and the 
incidence rate of RCC is higher, in a kidney transplantation 
group than in a control group. Moreover, Heinz-Peer et al. 
[12] analyzed 96 patients with ACKD detected by ultra-
sonography out of 385 renal transplant recipients in 1995 
and found that the incidence of ACKD was higher with lon-
ger duration times of dialysis before kidney trans-
plantation in older subjects and in males. However, only 
a few studies have been performed to determine the effect 
of transplantation itself on ACKD, and none have reported 
a clear effect on RCC. Ishikawa et al. [6], in their pro-
spective study following up the native kidney of 61 trans-
plant recipients by CT 1 to 2 years after transplantation, 
observed no renal cysts in 52.5% of the recipients, no 
change in the number of cysts in 14.8%, a decrease in the 
number of cysts in 14.8%, and an increase in the number Korean J Urol 2012;53:229-233
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in 17.9%. They explained that ACKD was caused by epi-
thelial hyperplasia following uremia and proposed that re-
solving the uremia in a successful transplantation could 
lead to the regression of ACKD.
In this study, the incidence of ACKD was lower in trans-
plant recipients than in dialysis patients. Because the 
transplant recipients had undergone dialysis before, the 
effect of dialysis could not be excluded completely for this 
group. However, previous studies reported that ACKD de-
velopment increases cancer risk in dialysis patients and 
transplant recipients after kidney transplantation. In our 
study, one of the cases of ACKD in a transplant recipient 
was found by routine examination (e.g., ultrasonogram or 
CT) (Table 1). The incidence rate of ACKD was lower in 
transplant recipients than in dialysis patients, and RCC 
not associated with ACKD in the transplant recipients. 
Although there have been some reports that trans-
plantation may lead to the regression of ACKD, it is difficult 
to say whether transplantation may reduce the risk of RCC, 
even though we found that there was a significantly longer 
time to the occurrence of RCC in the transplantation group 
than in the dialysis group. We considered that this was 
caused by the length of exposure to a uremic environment 
during dialysis before transplantation and the use of im-
munosuppressive agents after kidney transplantation. 
CONCLUSIONS
A comparison between renal transplant recipients and di-
alysis patients, all of whom had been surgically treated for 
RCC, except for one patient diagnosed by renal biopsy, 
found that the incidence rate of ACKD was significantly 
higher in the dialysis group. ACKD is known to be a potent 
risk factor for cancer among ESRD patients, and this study 
has further shown that ACKD is a cancer risk factor in dial-
ysis patients. However, cancer without ACKD was also ob-
served in transplant recipients. Considering that the recip-
ients had also undergone dialysis before transplantation, 
prospective studies will be necessary to determine whether 
the use of immunosuppressive agents, other than ACKD, 
may as also be a factor contributing to renal cancer risk. 
Renal transplant recipients and dialysis patients were at 
high risk of RCC. We propose that routine ultrasonograms 
or CT should be performed for follow-up in these high-risk 
patients. 
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